<DOC>
	<DOCNO>NCT02399566</DOCNO>
	<brief_summary>The purpose study compare effect erlotinib pemetrexed maintenance therapy lung adenocarcinoma . Primary Outcome progression free survival ( PFS ) . Based prediction different potential benefit group , study may help oncologist optimize improve maintenance therapy plan lung adenocarcinoma .</brief_summary>
	<brief_title>Clinical Trial Erlotinib Pemetrexed Maintenance Treatment Lung Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically diagnose stage III/IV Lung Adenocarcinoma ; Age 1875years ; Gender Not Required ; Received systemic clinical examination , include chest Xray , abdomen B ultrasound , head CT scan , radionuclide bone scan ; Received cisplatin chemotherapy 4 cycle study , curative effect chemotherapy SD SD ( efficacy evaluation time 21 day , SD , long diameter target lesion shall increase ) ; Adequate hematologic , renal , hepatic function , Specific index follow : liver function : SBilirubin ≤1.5 ULN ; Transaminase≤2 ULN . renal function : SCreatinine ≤1.2 ULN ; blood urea nitrogen ≤1.2 ULN . ULN : upper normal limit . Marrow Hemopoietic Function : WBC≥4.0×10^9/l , ANC≥2.0×10^9/l platelet count ≥100×10^9/l , Hb≥100 g/l ; ECOG PS 02 , Life expectancy ≥ 3 month ; endure two cycle chemotherapy ; The patient explicit lung tumor lesion lesion measurable ; ( According standard RECIST1.1 , least one accurately measurable lesion large diameter ≥ 10mm spiral CT , MRI ) ; No history serious drug allergy ; Informed consent obtain treatment . Not histologically cytologically diagnose Lung Adenocarcinoma The age &gt; 75 year &lt; 18 year . Major organ dysfunction Serious Heart Disease ( congestive heartfailure , incontrollable highrisk arrhythmia , unstable angina , alular disease , myocardial infarct Resistant hypertension , ) ; Serious complication investigator consider unsuited enrolling ; Pregnant lactate woman ; Allergic research drug ; Received cisplatin chemotherapy 4 cycle study , curative effect chemotherapy PD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>erlotinib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>